On this episode of Stock Movers:
- 3M (MMM) drops after the company said its' profit outlook fell narrowly short of Wall Street’s expectations for this year. Adjusted earnings will be $8.50 to $8.70 a share in 2026, the manufacturer said Tuesday in a statement. The midpoint was slightly below the $8.64 average of analyst estimates compiled by Bloomberg. Adjusted sales will climb about 4%, the company said.
- Strategy (MSTR) shares fall after the company acquired almost $2.13 billion in Bitcoin over the previous eight days, marking the digital asset treasury company’s largest purchase of the original cryptocurrency since July.
- ImmunityBio (IBRX) shares rise after the drug developer said it held a Type B End-of-Phase meeting with the US FDA regarding its supplemental application for its drug to treat bladder cancer. The FDA recommended that the company provide additional information to support a potential resubmission of the supplemental Biologics License Application (sBLA) for Anktiva in combination with Bacillus Calmette-Guérin (BCG.)

On this episode of Stock Movers: - 3M (MMM) drops after the company said its' profit outlook fell narrowly short of Wall Street&rsquo;s expectations for this year. Adjusted earnings will be $8.50 to $8.70 a share in 2026, the manufacturer said Tuesday in a statement. The midpoint was slightly below the $8.64 average of analyst estimates compiled by Bloomberg. Adjusted sales will climb about 4%, the company said. - Strategy (MSTR) shares fall after the company acquired almost $2.13 billion in Bitcoin over the previous eight days, marking the digital asset treasury company&rsquo;s largest purchase of the original cryptocurrency since July. - ImmunityBio (IBRX) shares rise after the drug developer said it held a Type B End-of-Phase meeting with the US FDA regarding its supplemental application for its drug to treat bladder cancer. The FDA recommended that the company provide additional information to support a potential resubmission of the supplemental Biologics License Application (sBLA) for Anktiva in combination with Bacillus Calmette-Gu&eacute;rin (BCG.)

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

3M Drops, Strategy Falls, ImmunityBio Drops After FDA Meeting Update  

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/30f763ee-6452-4b3a-afb4-b3d8010b3b7d/transcript